Cargando…

Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer

OBJECTIVE: Optimal approaches to patients with local recurrence of rectal cancer are unclear in China. This study aimed to evaluaty -30te the clinical outcomes and toxicity associated with different treatment regimens for patients with local recurrence of rectal cancer. METHODS: A retrospective char...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Zhongzhu, Liu, Luying, Liu, Dong, Wu, Lie, Lu, Ke, Zhou, Ning, Shen, Jinwen, Chen, Guiping, Liu, Guan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721123/
https://www.ncbi.nlm.nih.gov/pubmed/33299348
http://dx.doi.org/10.2147/CMAR.S278427
_version_ 1783619978743775232
author Tang, Zhongzhu
Liu, Luying
Liu, Dong
Wu, Lie
Lu, Ke
Zhou, Ning
Shen, Jinwen
Chen, Guiping
Liu, Guan
author_facet Tang, Zhongzhu
Liu, Luying
Liu, Dong
Wu, Lie
Lu, Ke
Zhou, Ning
Shen, Jinwen
Chen, Guiping
Liu, Guan
author_sort Tang, Zhongzhu
collection PubMed
description OBJECTIVE: Optimal approaches to patients with local recurrence of rectal cancer are unclear in China. This study aimed to evaluaty -30te the clinical outcomes and toxicity associated with different treatment regimens for patients with local recurrence of rectal cancer. METHODS: A retrospective chart review of patients with local recurrence of rectal cancer and previous radical surgical treatment between March 2010 and December 2017 with curative intent was performed. Disease-related endpoints included treatment progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method. Toxicities were assessed using Common Terminology Criteria for Adverse Events, version 5.0, and complications were scored according to the Clavien-Dindo classification. RESULTS: A total of 71 patients met the inclusion criteria in this study. The recurrence sites were mainly local recurrence in the pelvic cavity and regional lymph node metastasis. Twenty patients received chemoradiotherapy combined with surgery, 10 underwent surgery alone, and others received chemoradiotherapy-alone (n = 27) and chemotherapy-alone (n = 14) treatment. A clear difference was found in PFS between surgery/chemoradiotherapy with surgery and chemoradiotherapy/chemotherapy groups (26.6 months vs 14.1 months, P = 0.033). The PFS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 65.2 months, 20.2 months, and 14.2 months, respectively (P = 0.042). The multivariate analysis of PFS demonstrated that surgery was an independent factor. The proportion of patients with distant metastases after chemoradiotherapy/chemotherapy was higher than that of patients undergoing surgery (36.6% vs 21.4%, P = 0.179). The OS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 89.4 months, 66.0 months, and 62.8 months, respectively (P = 0.189). Radiation treatment and surgery did not increase extra severe toxicities. CONCLUSION: Surgery combined with chemoradiotherapy was a beneficial treatment mode for managing patients with locally recurrent, nonmetastatic rectal cancer. It was associated with better local disease control, no increase in toxicity, and prolonged survival among patients with locally recurrent rectal cancer.
format Online
Article
Text
id pubmed-7721123
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77211232020-12-08 Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer Tang, Zhongzhu Liu, Luying Liu, Dong Wu, Lie Lu, Ke Zhou, Ning Shen, Jinwen Chen, Guiping Liu, Guan Cancer Manag Res Original Research OBJECTIVE: Optimal approaches to patients with local recurrence of rectal cancer are unclear in China. This study aimed to evaluaty -30te the clinical outcomes and toxicity associated with different treatment regimens for patients with local recurrence of rectal cancer. METHODS: A retrospective chart review of patients with local recurrence of rectal cancer and previous radical surgical treatment between March 2010 and December 2017 with curative intent was performed. Disease-related endpoints included treatment progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method. Toxicities were assessed using Common Terminology Criteria for Adverse Events, version 5.0, and complications were scored according to the Clavien-Dindo classification. RESULTS: A total of 71 patients met the inclusion criteria in this study. The recurrence sites were mainly local recurrence in the pelvic cavity and regional lymph node metastasis. Twenty patients received chemoradiotherapy combined with surgery, 10 underwent surgery alone, and others received chemoradiotherapy-alone (n = 27) and chemotherapy-alone (n = 14) treatment. A clear difference was found in PFS between surgery/chemoradiotherapy with surgery and chemoradiotherapy/chemotherapy groups (26.6 months vs 14.1 months, P = 0.033). The PFS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 65.2 months, 20.2 months, and 14.2 months, respectively (P = 0.042). The multivariate analysis of PFS demonstrated that surgery was an independent factor. The proportion of patients with distant metastases after chemoradiotherapy/chemotherapy was higher than that of patients undergoing surgery (36.6% vs 21.4%, P = 0.179). The OS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 89.4 months, 66.0 months, and 62.8 months, respectively (P = 0.189). Radiation treatment and surgery did not increase extra severe toxicities. CONCLUSION: Surgery combined with chemoradiotherapy was a beneficial treatment mode for managing patients with locally recurrent, nonmetastatic rectal cancer. It was associated with better local disease control, no increase in toxicity, and prolonged survival among patients with locally recurrent rectal cancer. Dove 2020-11-30 /pmc/articles/PMC7721123/ /pubmed/33299348 http://dx.doi.org/10.2147/CMAR.S278427 Text en © 2020 Tang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tang, Zhongzhu
Liu, Luying
Liu, Dong
Wu, Lie
Lu, Ke
Zhou, Ning
Shen, Jinwen
Chen, Guiping
Liu, Guan
Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer
title Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer
title_full Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer
title_fullStr Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer
title_full_unstemmed Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer
title_short Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer
title_sort clinical outcomes and safety of different treatment modes for local recurrence of rectal cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721123/
https://www.ncbi.nlm.nih.gov/pubmed/33299348
http://dx.doi.org/10.2147/CMAR.S278427
work_keys_str_mv AT tangzhongzhu clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT liuluying clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT liudong clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT wulie clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT luke clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT zhouning clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT shenjinwen clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT chenguiping clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer
AT liuguan clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer